Seladelpar lysine dihydrate for the treatment of patients with primary biliary cholangitis

30 July 2025 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...

Read more →

FDA approves Alhemo as once daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with haemophilia A or B without inhibitors

31 July 2025 - FDA approval is based on phase 3 trial data (explorer8), which established the safety and efficacy of ...

Read more →

Serplulimab in combination with carboplatin and etoposide phosphate for the first-line treatment of patients with extensive-stage small-cell lung cancer

30 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

BeOne Medicines receives PRIME designation from the EMA for BGB-16673 in Waldenström’s macroglobulinaemia

31 July 2025 - Decision highlights the promise of BGB-16673, an investigational and potentially first in class BTK degrader designed ...

Read more →

Reimbursement for oral Fabry disease drug Galafold expanded to first-line treatment

1 August 2025 - Handok's Fabry disease treatment, Galafold (migalastat), will have its insurance coverage criteria expanded to include first-line ...

Read more →

Lenz Therapeutics announces US FDA approval of Vizz for the treatment of presbyopia

31 July 2025 - Vizz samples and product availability in the US expected as early as October 2025. ...

Read more →

Norgine welcomes PBS listing in Australia of Ifinwil (eflornithine) for patients with high-risk neuroblastoma

1 August 2025 - Approximately 50 children in Australia are diagnosed with neuroblastoma each year, with nearly half classified as having ...

Read more →

Trump takes aim at ‘foreign freeloading nations’ over drug prices in new threat to PBS

1 August 2025 - US President Donald Trump has blamed “foreign freeloading nations” for the high drug prices faced by ...

Read more →

Novartis twice yearly Leqvio (inclisiran) receives FDA approval for new indication enabling first-line use

31 July 2025 - 4 out of 5 atherosclerotic cardiovascular disease patients do not reach guideline-recommended LDL-C target, reinforcing urgent need ...

Read more →

ICER to assess therapies for IgA nephropathy

31 July 2025 - Report will be subject of CTAF meeting in February 2026; draft scoping document open to public ...

Read more →

US FDA approves new Biktarvy indication for people with HIV who are treatment experienced and restarting antiretroviral treatment

30 July 2025 -  Gilead Sciences today announced that the US FDA has granted a new approval for a novel ...

Read more →

Dostarlimab in combination with platinum-based chemotherapy for the treatment of patients with advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency

30 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Schedule of Pharmaceutical Benefits - 1 August 2015

1 August 2025 - The August 2025 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...

Read more →

Revalesio receives FDA fast track designation for RNS60 for the treatment of acute ischaemic stroke

31 July 2025 - Revalesio today announced that the US FDA has granted fast track designation to RNS60, its lead investigational ...

Read more →

New Zealand Pharmaceutical Schedule - 1 August 2025

1 August 2025 - - The August 2025 issue of the New Zealand Pharmaceutical Schedule is now available and in ...

Read more →